VIRTUS THERAPEUTICS CORPORATION

Biotech · Private

Small-molecule PANK3 activators (VTAC1-9) to treat pantothenate kinase-associated neurodegeneration

Grants
$797K
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · PANK Activators for the treatment of pantothenate kinase-associated neurodegeneration$359,552
Federal grantDepartment of Health and Human Services · Phase I · PANK Activators for the treatment of pantothenate kinase-associated neurodegeneration$338,249
Federal grantDepartment of Health and Human Services · Phase I · PANK Activators for the treatment of pantothenate kinase-associated neurodegeneration$99,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2759Lassen Therapeutics——
2760ORGANIX, INC.——
2761KOLIBER BIOSCIENCES INC.——
2762VIRTUS THERAPEUTICS CORPORATION——
2763SPECIFICA, INC.——
2764SAFI BIOTHERAPEUTICS INC——
2765NANOVALENT PHARMACEUTICALS INC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.